Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population

Kumar, Atul; Sinha, Subijay
November 2007
Indian Journal of Ophthalmology;Nov2007, Vol. 55 Issue 6, p451
Academic Journal
journal article
Background: To report the anatomic and visual acuity response after intravitreal bevacizumab (Avastin) in patients with diffuse diabetic macular edema.Design: Prospective, interventional case series study.Materials and Methods: This study included 20 eyes of metabolically stable diabetes mellitus with diffuse diabetic macular edema with a mean age of 59 years who were treated with two intravitreal injections of bevacizumab 1.25 mg in 0.05 ml six weeks apart. Main outcome measures were 1) early treatment diabetic retinopathy study visual acuity, 2) central macular thickness by optical coherence tomography imaging. Each was evaluated at baseline and follow-up visits.Results: All the eyes had received some form of laser photocoagulation before (not less than six months ago), but all of these patients had persistent diffuse macular edema with no improvement in visual acuity. All the patients received two injections of bevacizumab at an interval of six weeks per eye. No adverse events were observed, including endophthalmitis, inflammation and increased intraocular pressure or thromboembolic events in any patient. The mean baseline acuity was 20/494 (log Mar=1.338+/-0.455) and the mean acuity at three months following the second intravitreal injection was 20/295 (log Mar=1.094+/-0.254), a difference that was highly significant ( P =0.008). The mean central macular thickness at baseline was 492 microm which decreased to 369 microm ( P =0.001) at the end of six months.Conclusions: Initial treatment results of patients with diffuse diabetic macular edema not responding to previous photocoagulation did not reveal any short-term safety concerns. Intravitreal bevacizumab resulted in a significant decrease in macular thickness and improvement in visual acuity at three months but the effect was somewhat blunted, though still statistically significant at the end of six months.


Related Articles

  • Sonepcizumab, anti-VEGF may yield long-term visual acuity. Charters, Lynda // Ophthalmology Times;11/15/2016, Vol. 41 Issue 19, p26 

    The article reports on the Nexus Study on the monoclonal antibody sonepcizumab and its effect of improving visual acuity and potential for long-term stabilization for patients diagnosed with age-related macular degeneration (AMD). Topics include the efficacy of sonepcizumab monotherapy and in...

  • VMA does not affect visual acuity after anti-VEGF injections for polypoidal choroidal vasculopathy. Kronemyer, Bob // Ocular Surgery News;2/25/2014, Vol. 32 Issue 4, p26 

    The article reports that posterior vitreomacular adhesion (VMA) was not associated with visual outcomes after intravitreal anti-vascular endothelial growth factor (VEGF) therapy for polypoidal choroidal vasculopath based on a study led by ophthalmologist Dr. Han Joo Cho. Topics discussed include...

  • Repeated anti-VEGF injections may alter RNFL thickness. Biro, Ashley // Ocular Surgery News;2/10/2013, Vol. 31 Issue 3, p21 

    The article discusses that anti vascular endothelial growth factor (anti-VEGF) injections can alter retinal nerve fiber layer (RNFL) thickness.

  • Scrutinizing injection protocols. McDonnell, Peter J. // Ophthalmology Times;Jun2015, Vol. 40 Issue 10, p6 

    The author reflects on a case of endophthalmitis, accompanied by vision loss, following an anti-vascular endothelial growth factor (VEGF) intravitreal injection for management of age-related macular degeneration (AMD). Topics covered include the risk of infection associated with intravitreal...

  • Ranibizumab: In Diabetic Macular Oedema. Frampton, James E. // Drugs;2012, Vol. 72 Issue 4, p509 

    Ranibizumab, an intravitreally administered in-hibitor of vascular endothelial growth factor (VEGF), is approved for the treatment of visual impairment associated with diabetic macular oedema (DME) in the EU. In four well designed, phase II or III trials (RE-SOLVE, RESTORE, RIDE and RISE), 1-2...

  • First injections can predict anti-VEGF success in DME. Harrison, Laird // Ophthalmology Times;1/1/2016, Vol. 41 Issue 1, p29 

    The article reviews research indicating that clinicians can predict a patient's long-term response to anti-vascular endothelial growth factor (VEGF) treatment of diabetic macular edema (DME) after three injections. Topics include researchers Doctor Pravin Dugel and colleagues conducting a post...

  • Treat-and-extend treatment benefits maintained at 3 years. Nale, Patricia; Swartz, Shauna // Ocular Surgery News;9/25/2014, Vol. 32 Issue 18, p24 

    The article focuses on a study presented at the 2014 American Society of Retina Specialists (ASRS) annual meeting in San Diego, California which found a treat-and-extend regimen for neovascular age-related macular degeneration has sustained mean visual acuity and anatomical improvements for 3 years.

  • Ranibizumab: points to consider when using it to treat neovascular age-related macular degeneration according to EU labelling. Lyseng-Williamson, Katherine; Frampton, James // Drugs & Therapy Perspectives;Sep2013, Vol. 29 Issue 9, p268 

    Ranibizumab (Lucentis), an inhibitor of multiple vascular endothelial growth factor A isoforms, is approved for the intravitreal treatment of neovascular (wet) age-related macular degeneration (AMD). In clinical trials in patients with neovascular AMD, monthly or less frequent injections of...

  • OPTIMAL MANAGEMENT OF NEOVASCULAR AMD: WHEN TO TREAT? WHAT TO TREAT? HOW TO TREAT?  // Johns Hopkins Advanced Studies in Ophthalmology;Nov2013, Vol. 10 Issue 3, p57 

    An introduction is presented in which the author discusses the advancement in diagnostic imaging and the strategies for treating age-related macular degeneration (AMD).

  • Vitreomacular interface affects anti-VEGF injection intervals for AMD. Ahem, Steve; Hasson, Matt // Ocular Surgery News;4/25/2014, Vol. 32 Issue 8, p17 

    The article discusses a study which shows that anti-vascular endothelial growth factor (VEGF) injection intervals for the management of age-related macular degeneration is affected by vitreomacular interface disease.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics